Summary of patient characteristics, treatment, and outcome

No. of Patients (N = 13)
Male sex11 (84.6%)
Age (mean ± SD) (yr)56 ± 6.2
Pretreatment NIHSS (mean ± SD)26 ± 4
Symptom-to-door time (mean ± SD) (min)587 ± 341
Needle-to-recanalization (mean ± SD) (min)93 ± 28
Door-to-reperfusion (mean ± SD) (min)301 ± 117
Underlying site of stenosis
    BA10 (76.9%)
    V43 (13%)
Endovascular treatment for the stenosis
    PTA alone3 (23.1%)
    Apollo stent3 (23.1%)
    Wingspan stent7 (53.8%)
Glycoprotein IIb/IIIa inhibitor6 (46.2%)
Pre-PTA/stenting stenosis (mean ± SD)91.5 ± 2.4%
Post-PTA/stenting stenosis (mean ± SD)24.6 ± 12.6%
Pre-PTA/stenting TICI (post-mechanical thrombectomy)
    02 (5.4%)
    17 (53.8%)
    2a4 (30.8%)
Post-PTA/stenting TICI
    2b3 (23.1%)
    310 (76.9%)
Distal embolization to PCA/cerebellar arteries3 (23.1%)
Outcome
    NIHSS score on discharge for surviving patients (mean ± SD)12 ± 6
    % of patients with NIHSS ≥10-point improvement10 (79.9%)
    Mortality on discharge2 (15.3%)
    mRS at 90 days
        mRS 0–26 (46.2%)
        mRS 0–39 (69.2%)
    Ischemic events at 90-day follow-up0 (0%)
  • Note:—BA indicates basilar artery; PCA, posterior cerebral artery; V4, vertebral artery V4 segment.